AAIC 2024 | The clinical use of tau-PET: its value and limitations

Cécile Tissot, PhD, University of California, Berkeley, CA, comments on the value of tau positron emission tomography (PET) in Alzheimer’s disease (AD). She highlights that the visualization of tau accumulation in the brain can be correlated with cognitive impairment to aid in AD diagnosis. However, the high cost, limited availability of cyclotrons, and the use of radioactivity are significant challenges to widespread implementation. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.